Regeneron Pharmaceuticals, one of the companies taking on Covid-19 has been making news recently — both very good and not so much. So it was fortuitous that I had the chance to talk with the head of its clinical operations.
In the third episode of Pivot, Bari Kowal, Regeneron’s vice president of global clinical operations, provides us insight into the pharma company’s efforts to halt the march of the novel coronavirus. But equally importantly, she reflects on the broad changes that must be instituted to overhaul clinical trials while also working to lower prices and improve access.
